Extract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing lung disease that leads to unrelenting dyspnoea and chronic cough, and ultimately respiratory failure [1]. IPF is characterised by a variable disease course that remains difficult to predict for an individual at diagnosis [2]. In the current era, with the advent of anti-fibrotic therapy which can slow disease progression, it is increasingly important to identify patients with early disease and to target those patients who are at most risk of rapid decline [3]. However, despite multiple studies proposing novel potential prognostic biomarkers, the current American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society guideline statements dismissed the use of these biomarkers except in a research capacity [3, 4].
Abstract
Blood monocytes have been recently proposed as a potential prognostic marker for IPF. Data from the Australian IPF registry have shown that elevated monocytes, neutrophils and total leukocytes significantly predict poorer survival in IPF patients. http://bit.ly/38GP7f0
Footnotes
Conflict of interest: A.K.Y. Teoh reports personal fees from Roche and Boehringer, outside the submitted work.
Conflict of interest: H.E. Jo has nothing to disclose.
Conflict of interest: D.C. Chambers has nothing to disclose.
Conflict of interest: K. Symons has nothing to disclose.
Conflict of interest: E.H. Walters has nothing to disclose.
Conflict of interest: N.S. Goh has nothing to disclose.
Conflict of interest: I. Glaspole reports personal fees from Boehringer Ingelheim, Avalyn and Roche, outside the submitted work.
Conflict of interest: W. Cooper has nothing to disclose.
Conflict of interest: P. Reynolds has nothing to disclose.
Conflict of interest: Y. Moodley reports advisory board membership for Roche and Boehringer Ingelheim, outside the submitted work.
Conflict of interest: T.J. Corte reports grants, personal fees for advisory board work and lectures, and travel support from Boehringer, grants and personal fees for advisory board work and lectures from Roche, grants from Galapagos, Actelion, Bayer and Sanofi, personal fees for advisory board work from AstraZeneca, outside the submitted work.
- Received September 19, 2019.
- Accepted December 6, 2019.
- Copyright ©ERS 2020